Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Diffuse Large B-Cell Lymphoma · Follicular Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 543 (final count)
- Started
- Nov 3, 2020
- Main results expected
- Sep 30, 2027
- Fully finished
- Sep 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants With Dose limiting Toxicities (DLTs)
Measured over: During the first cycle (Cycle length= 28 days) in each cohort
Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)
Measured over: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
Part 2 (Except Arm 7): Overall Response Rate (ORR)
Measured over: Up to 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04663347 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC